Arthritis

Arthritis / 2015 / Article / Tab 3

Clinical Study

The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

Table 3

WOMAC subset and total scores.

Median scoreMedian change Median 
% change
BaselineWeek 12

WOMAC-A
 Diclofenac29.015.0−13.5*−48.1*
(28.0, 31.0)(13.0, 17.0)(−16.0, −11.0)(−55.2, −40.0)
 Wobenzym31.019.0−12.5*−39.7*
(30.0, 31.0)(17.0, 23.0)(−15.0, −10.0)(−47.1, −28.0)
 Placebo30.021.0−8.0*−28.1*
(28.0, 31.0)(17.0, 25.0)(−13.0, −5.0)(−44.8, −16.7)
WOMAC-B
 Diclofenac12.06.0−4.0*−43.7*
(11.0, 13.0)(5.0, 7.0)(−6.0, −3.0)(−57.1, −21.4)
 Wobenzym11.08.0−4.0*−33.3*
(10.0, 12.0)(6.0, 8.0)(−4.0, −3.0)(−41.7, −27.3)
 Placebo12.08.0−3.0*−26.2*
(10.0, 13.0)(6.0, 10.0)(−4.0, −2.0)(−35.7, −16.7)
WOMAC-C
 Diclofenac100.053.0−32.0*−36.2*A
(93.0, 106.0)(45.0, 64.0)(−47.0, −20.0)(−54.7, −24.0)
 Wobenzym101.570.0−28.5*−30.3*AB
(96.0, 108.0)(65.0, 82.0)(−37.0, −20.0)(−39.4, −21.1)
 Placebo102.075.0−19.0*−19.7*B
(92.0, 107.0)(66.0, 88.0)(−27.0, −14.0)(−34.3, −12.7)
WOMAC total
 Diclofenac136.574.0−50.0*−38.3*A
(133.0, 146.0)(62.0, 86.0)(−73.0, −25.0)(−54.4, −28.8)
 Wobenzym142.596.0−46.5*−35.5*AB
(136.0, 153.0)(88.0, 114.0)(−57.0, −34.0)(−39.4, −21.1)
 Placebo144.5101.5−26.5*−17.3*B
(129.0, 151.0)(92.0, 123.0)(−51.0, −22.0)(−36.6, −12.5)

All values presented as medians (95% confidence interval).
*Significantly different from “no change” ( < 0.05).
A,BTreatment groups with different superscripts differ within the same column ( < 0.05).

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.